Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Crit Care Sci ; 36: e20240049en, 2024.
Article de Anglais, Portugais | MEDLINE | ID: mdl-38922237

RÉSUMÉ

Boswellia serrata is an herbal extract from the Boswellia serrata tree that has anti-inflammatory and analgesic properties and alleviates pain caused by rheumatoid arthritis, gout, osteoarthritis, and sciatica. Syndrome of inappropriate antidiuretic hormone secretion accompanied by hyponatremia, seizures, and rhabdomyolysis as a manifestation of Boswellia serrata intoxication has not been reported previously. A 38-year-old female suffered clinically isolated syndrome and has since been regularly taking B. serrata capsules (200mg/d) to strengthen her immune system. She experienced hypersensitivity to light, ocular pain, nausea, dizziness, and lower limb weakness four days after receiving her first BNT162b2 vaccine dose, and she increased the dosage of B. serrata to five capsules (1000mg/d) one week after vaccination. After taking B. serrata at a dosage of 1000mg/d for 3 weeks, she was admitted to the intensive care unit because of a first, unprovoked generalized tonic-clonic seizure. The patient's workup revealed syndrome of inappropriate antidiuretic hormone secretion, which resolved completely upon treatment and discontinuation of B. serrata. In summary, B. serrata potentially causes syndrome of inappropriate antidiuretic hormone secretion when it is taken at high doses. Patients should not self-medicate.


Sujet(s)
Boswellia , Hyponatrémie , Syndrome de sécrétion inappropriée d'ADH , Rhabdomyolyse , Crises épileptiques , Humains , Femelle , Adulte , Syndrome de sécrétion inappropriée d'ADH/diagnostic , Syndrome de sécrétion inappropriée d'ADH/induit chimiquement , Hyponatrémie/induit chimiquement , Hyponatrémie/étiologie , Rhabdomyolyse/induit chimiquement , Rhabdomyolyse/diagnostic , Crises épileptiques/étiologie , Crises épileptiques/induit chimiquement , Extraits de plantes/effets indésirables
2.
Braz J Biol ; 83: e272466, 2023.
Article de Anglais | MEDLINE | ID: mdl-37851769

RÉSUMÉ

Alzheimer's disease (AD) is the most common neurodegenerative disease characterized by hippocampal, and cortical neuron deterioration, oxidative stress, and severe cognitive dysfunction. Aluminum is a neurotoxin inducer for cognitive impairments associated with AD. The treatment approaches for AD are unsatisfactory. Boswellia papyrifera and Syzygium aromaticum are known for their pharmacological assets, including antioxidant activity. Therefore, the current study explored the possible mitigating effects of a combination of Boswellia papyrifera and Syzygium aromaticum against aluminum chloride (AlCl3) induced AD. The AD model was established using AlCl3 (100 mg/kg), and the rats were orally administrated with Boswellia papyrifera or Syzygium aromaticum or a combination of them daily for 8 weeks. The Y-maze test was used to test cognition in the rats, while acetylcholinesterase (AChE) and oxidative stress markers were estimated in homogenates of the cerebral cortex and hippocampus. Also, the histopathological examination of the cortex and hippocampus were investigated. The results revealed that administration of either B. papyrifera or S. aromaticum extracts significantly improved the cognitive functions of AD rats, enhanced AChE levels, increased oxidative enzymes levels, including SOD and GSH, and reduced MDA levels in homogenates of the cerebral cortex and hippocampus and confirmed by improvement in histological examination. However, using a combination therapy gave better results compared to a single treatment. In conclusion, the present study provided primary evidence for using a combination of B. papyrifera and S. aromaticum to treat cognitive dysfunction associated with AlCl3 Induced AD by improving the AChE levels and modulating oxidative stress in the brain.


Sujet(s)
Maladie d'Alzheimer , Boswellia , Maladies neurodégénératives , Neuroprotecteurs , Syzygium , Mâle , Rats , Animaux , Chlorure d'aluminium/toxicité , Chlorure d'aluminium/usage thérapeutique , Maladie d'Alzheimer/induit chimiquement , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/anatomopathologie , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/usage thérapeutique , Syzygium/métabolisme , Boswellia/métabolisme , Composés de l'aluminium/toxicité , Composés de l'aluminium/usage thérapeutique , Chlorures/toxicité , Chlorures/usage thérapeutique , Acetylcholinesterase/métabolisme , Maladies neurodégénératives/traitement médicamenteux , Rat Wistar , Stress oxydatif
3.
Molecules ; 24(7)2019 Mar 30.
Article de Anglais | MEDLINE | ID: mdl-30934998

RÉSUMÉ

Leishmaniasis is a neglected tropical disease caused by members of the Leishmania genus of parasitic protozoa that cause different clinical manifestations of the disease. Current treatment options for the cutaneous disease are limited due to severe side effects, poor efficacy, limited availability or accessibility, and developing resistance. Essential oils may provide low cost and readily available treatment options for leishmaniasis. In-vitro screening of a collection of 52 commercially available essential oils has been carried out against promastigotes of Leishmania amazonensis. In addition, cytotoxicity has been determined for the essential oils against mouse peritoneal macrophages in order to determine selectivity. Promising essential oils were further screened against intracellular L. amazonensis amastigotes. Three essential oils showed notable antileishmanial activities: frankincense (Boswellia spp.), coriander (Coriandrum sativum L.), and wintergreen (Gualtheria fragrantissima Wall.) with IC50 values against the amastigotes of 22.1 ± 4.2, 19.1 ± 0.7, and 22.2 ± 3.5 µg/mL and a selectivity of 2, 7, and 6, respectively. These essential oils could be explored as topical treatment options for cutaneous leishmaniasis.


Sujet(s)
Antiprotozoaires/composition chimique , Leishmania/composition chimique , Huile essentielle/composition chimique , Animaux , Antiprotozoaires/pharmacologie , Boswellia/composition chimique , Lignée cellulaire , Survie cellulaire/effets des médicaments et des substances chimiques , Coriandrum/composition chimique , Évaluation préclinique de médicament/méthodes , Concentration inhibitrice 50 , Leishmaniose cutanée/métabolisme , Macrophages péritonéaux/composition chimique , Souris de lignée BALB C , Huile essentielle/pharmacologie
4.
Phytother Res ; 31(11): 1676-1685, 2017 Nov.
Article de Anglais | MEDLINE | ID: mdl-28872719

RÉSUMÉ

Herbal medications are commonly used to manage symptoms associated with osteoarthritis (OA). This systematic review evaluated the effectiveness and safety of oral medications used in Brazil for the treatment of OA. Randomized clinical trials involving adults with OA treated by a herbal medicine or a control group were eligible. The primary outcomes measured were pain, physical function, swelling, stiffness and quality of life; and the secondary outcomes were adverse events, activity limitations and treatment satisfaction. Sixteen studies were included (n = 1,741 patients) in the systematic review and nine studies in the meta-analysis, representing 6 of the 13 herbal medicines studied: Boswellia serrata (n = 2), Curcuma longa (n = 3), Harpagophytum procumbens (n = 1), Salix daphnoides (n = 3), Uncaria guianensis (n = 2) and Zingiber officinale (n = 5). B. serrata was more effective than both placebo and valdecoxib for improvement of pain and physical function. No difference was observed for H. procumbens, C. longa and U. guianensis compared with control. Z. officinale showed improvement of pain over placebo. The evidence was insufficient to support the effective and safe use of these herbal medicines, because the quality of evidence of studies was low. This study guides managers of the Brazilian public health system and prescribers in decision-making regarding the use of these herbal medicines for OA. Copyright © 2017 John Wiley & Sons, Ltd.


Sujet(s)
Arthrose/traitement médicamenteux , Phytothérapie , Préparations à base de plantes/usage thérapeutique , Boswellia/composition chimique , Brésil , Curcuma/composition chimique , Zingiber officinale/composition chimique , Harpagophytum/composition chimique , Science des plantes médicinales , Humains , Plantes médicinales/composition chimique , Essais contrôlés randomisés comme sujet , Salix/composition chimique , Uncaria/composition chimique
5.
Syst Rev ; 5: 86, 2016 May 21.
Article de Anglais | MEDLINE | ID: mdl-27209428

RÉSUMÉ

BACKGROUND: Osteoarthritis affects 1 % of the world's population and is the most common cause of musculoskeletal impairment in the elderly. Herbal medications are commonly used in Brazil to manage symptoms associated with osteoarthritis, and some of them are financed by the Brazilian government; however, the effectiveness of most of these agents is uncertain. The aim was to systematically review the efficacy and safety of 13 oral herbal medications used in Brazil for the treatment of osteoarthritis. METHODS: Randomized clinical trials eligible for our systematic review will enroll adults with osteoarthritis treated by a Brazilian herbal medication or a control group (placebo or active control). Using terms to include all forms of osteoarthritis combined with herbal medications, we will search the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; CINAHL; Web of Science; Health Star; AMED, the database of the Cochrane Complementary Medicine Field, LILACS; CAB abstracts, Clinical trial.gov, WHO trials registry, and Bank of Brazil Thesis (CAPES), to 31 January 2016, without restrictions concerning language or status of publication. Outcomes of interest include the following: symptom relief (e.g., pain), adverse events (gastrointestinal bleeding, epigastric pain, nausea, and allergic reactions), discontinuation due to adverse events, quality of life, and the satisfaction with the treatment. Dichotomous data will be summarized as risk ratios; continuous data will be given as standard average differences with 95 % confidence intervals. A team of reviewers will assess each citation independently for eligibility and in duplicate it. For eligible studies, the same reviewers will perform data extraction, bias risk assessment, and determination of the overall quality of evidence for each of the outcomes using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) classification system. DISCUSSION: This is the first study that will evaluate the use of herbal medications used in Brazil for the treatment of pain caused by osteoarthritis. The results could guide prescribers in decision-making in clinical practice, to inform the patients with pain caused by osteoarthritis in relation to effective and safe treatment options and to inform the managers of the public health system which of the plants could actually be financed by the Brazilian government. SYSTEMATIC REVIEW REGISTRATION: PROSPERO 42015019793.


Sujet(s)
Arthrose/traitement médicamenteux , Phytothérapie , Préparations à base de plantes/usage thérapeutique , Boswellia , Brésil , Griffe de chat , Chenopodium ambrosioïdes , Cordia , Curcuma , Fabaceae , Harpagophytum , Humains , Persea , Salix , Revues systématiques comme sujet , Résultat thérapeutique , Uncaria
6.
Phytother Res ; 28(9): 1392-8, 2014 Sep.
Article de Anglais | MEDLINE | ID: mdl-24619538

RÉSUMÉ

Ulcerative colitis is an inflammatory disease that involves only the colon and rectum, being characterized by leukocyte infiltrate and superficial ulcers in the intestinal mucosa. To evaluate the anti-inflammatory and antioxidant effects of extract from the Boswellia serrata plant in an experimental rat model of acute ulcerative colitis induced by the administration of acetic acid (AA). An extract of B. serrata (34.2 mg/kg/day) was administered by oral gavage for 2 days before and after the induction of colitis with 4 mL of 4% AA. The anal sphincter pressure in the colitis group showed a significant decrease compared to that of the control groups (p < 0.001). The analysis of the values of lipid peroxidation (LPO) obtained by substances that react with thiobarbituric acid (TBARS) showed a significantly increased LPO in the colitis group compared to the control groups (p < 0.001). The nitric oxide levels and the expression of inducible nitric oxide synthase (iNOS) showed a significant increase in the colitis group compared to control groups (p < 0.01). Both pretreatment and treatment with B. serrata exhibited significantly reduced lipid peroxidation, nitric oxide and iNOS and showed improvements in tissue injury and anal sphincter pressure in animals with ulcerative colitis. The B. serrata extract has protective anti-inflammatory and antioxidant effects that inhibit inflammatory mediators in acute experimental colitis.


Sujet(s)
Anti-inflammatoires/pharmacologie , Antioxydants/pharmacologie , Boswellia/composition chimique , Rectocolite hémorragique/traitement médicamenteux , Extraits de plantes/pharmacologie , Animaux , Rectocolite hémorragique/induit chimiquement , Côlon/anatomopathologie , Modèles animaux de maladie humaine , Peroxydation lipidique , Mâle , Monoxyde d'azote/métabolisme , Nitric oxide synthase type II/métabolisme , Rats , Rat Wistar , Substances réactives à l'acide thiobarbiturique/métabolisme
7.
Dig Dis Sci ; 57(8): 2038-44, 2012 Aug.
Article de Anglais | MEDLINE | ID: mdl-22451119

RÉSUMÉ

AIM OF THE STUDY: To evaluate the antioxidant effect of an extract of the plant Boswellia serrata in an experimental model of acute ulcerative colitis induced by administration of acetic acid (AA) in rats. MATERIALS AND METHODS: The extract of B. serrata (34.2 mg/kg/day) was administered orally by gavage for 2 days before and after induction of colitis with AA diluted to 4 % and in a volume of 4 ml. RESULTS: The anal sphincter pressure in the groups treated with B. serrata showed a significant increase compared to the colitis group (P < 0.001). Histological analysis of treated animals showed less edema with preservation of mucosal crypts. Lipid peroxidation showed a significant decrease in the treated groups compared to the colitis group (P < 0.001). The superoxide dismutase (SOD) enzyme activity showed a significant reduction in the treated groups compared to the colitis group (P < 0.001), the glutathione peroxidase (GPx) significantly increased in the treated groups compared to colitis group (P < 0.05), and the same was the result for enzyme activity glutathione (GSH; P < 0.05). CONCLUSIONS: The extract of B. serrata has active antioxidant substances that exert protective effects in acute experimental colitis.


Sujet(s)
Boswellia , Colite/traitement médicamenteux , Stress oxydatif/effets des médicaments et des substances chimiques , Phytothérapie , Extraits de plantes/usage thérapeutique , Acide acétique , Canal anal/effets des médicaments et des substances chimiques , Animaux , Colite/anatomopathologie , Côlon/anatomopathologie , Modèles animaux de maladie humaine , Évaluation préclinique de médicament , Glutathion/métabolisme , Glutathione peroxidase/métabolisme , Peroxydation lipidique/effets des médicaments et des substances chimiques , Mâle , Extraits de plantes/pharmacologie , Rats , Rat Wistar , Superoxide dismutase/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE